AbbVie And C2N Enter Into A Worldwide License Agreement For Alzheimer's Disease Therapy
NORTH CHICAGO, Ill.,March 19, 2015/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it has entered into an exclusive worldwide license agreement with C2N Diagnostics, a privately held protein diagnostic and therapeutic discovery company, to develop and commercialize a portfolio of anti-tau antibodies for the treatment of Alzheimer's Disease and other neurological disorders. This partnership builds upon AbbVie's commitment to pursue transformational disease-modifying therapies in Alzheimer's Disease.
Abbvie的皮肤病学领导力在美国皮肤病学会2015年会议上以Humira®（Adalimumab）数据展示
NORTH CHICAGO, Ill.,March 17, 2015/PRNewswire/ -- AbbVie (NYSE: ABBV) announced that data from 22 abstracts on HUMIRA® (adalimumab) and dermatological diseases will be presented at the upcoming 73rd Annual Meeting of the American Academy of Dermatology (AAD),March 20- 24，在旧金山。阿布维（Abbvie）在AAD的存在表明了该公司对基于Humira的皮肤病学领域的承诺。Humira是可用的最全面研究的生物制剂之一，并以皮肤病学领域的医师和患者经验为特色。
AbbVie to Present at Barclays Global Health Care Conference
NORTH CHICAGO, Ill.,March 6, 2015/PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Barclays Global Health Care Conference onThursday, March 12, 2015。Richard A. Gonzalez, chairman and chief executive officer, will participate in a question and answer session at8:30 a.m. Central time。
AbbVie以获取药物含量，包括其重磅炸弹产品Imbruvica®，创建了一个行业领先的血液学肿瘤专营权
NORTH CHICAGO, Ill.和SUNNYVALE, Calif.,March 4, 2015/ PRNEWSWIRE/ -ABBVIE（NYSE：ABBV）和Pharmacyclics（NASDAQ：PCYC）今天宣布了一项确定的协议，ABBVIE将获得药物验证企业及其旗舰资产Imbruvica®（Ibrutinib），这是对血液恶性肿瘤的高效治疗。此次收购加速了Abbvie在肿瘤学中的临床和商业形象，加强了已经强大的管道，并在血液学肿瘤学中建立了强大的领导地位 - 一个有吸引力且快速增长的市场，现在正在接近$24全球十亿。此次收购增加了Abbvie已经全面的管道和强劲的增长前景。
AbbVie's HUMIRA® (Adalimumab) Receives Positive CHMP Opinion to Treat Children and Adolescents With Severe Chronic Plaque Psoriasis
– Marketing Authorization Decision Expected from the European Commission in the Second Quarter –
AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting
NORTH CHICAGO, Ill.,Feb. 26, 2015/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that 15 abstracts of studies in its neuroscience and oncology development programs have been accepted for presentation during the 67th美国神经病学会年会Washington, D.C., from4月18日至25日。公认的摘要功能来自评估Abbvie的FDA批准产品Duopa的研究结果。演讲将包括对多形胶质母细胞瘤患者的ABT-414研究的1阶段结果，Zinbryta™的第3阶段数据（Daclizumab高收益过程）与Biogen IDEC共同开发，在复发中恢复恢复多发性硬化症和结果，以及结果。根据对晚期帕金森氏病的Duopa（Carbidopa和Levodopa）肠道悬架的研究。
Abbvie参加Cowen第35届年度卫生保健会议
NORTH CHICAGO, Ill.,Feb. 25, 2015/PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Cowen 35th年度卫生保健会议Wednesday, March 4, 2015。Bill Chase执行副总裁兼首席财务官，将在公司上进行演讲，并在9 a.m. Central time。
Abbvie对Viekira Pak™的研究（Ombitasvir，Paritaprevir，Ritonavir片； Dasabuvir片剂）在HIV-1共同感染（Turquoise-I）在JAMA在线出版的慢性丙型肝炎患者（turquoise-i）；将在年度同盟中呈现的子分析
NORTH CHICAGO, Ill.,2015年2月23日/PRNEWSWIRE/ - ABBVIE（NYSE：ABBV）今天宣布，在基因型1慢性肝炎患者中，其阶段2/3开放标签研究的第2阶段一部分的结果是人类免疫缺陷病毒1型的基因型肝炎患者（HIV-1）共同感染已在线发布美国医学协会杂志（JAMA）。在口头和海报演示中也将介绍其他子肛门。Feb. 26在逆转录病毒和机会感染年度会议上（CROI）Seattle, Wash.
Abbvie在日本提交了新的药物申请，以研究其慢性肝炎的研究，全口治疗
NORTH CHICAGO, Ill.,Feb. 11, 2015/PRNewswire/ -- AbbVie (NYSE: ABBV) submitted a New Drug Application (NDA) to the Japanese Ministry of Health, Labour and Welfare (MHLW) seeking approval for the company's investigational, all-oral, ribavirin (RBV) and interferon (IFN)-free, 12-week, two direct-acting antiviral treatment of ombitasvir/paritaprevir/ritonavir (OBV/PTV/r), dosed once daily. The submission is for the treatment of patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection.